TrialEuropean heart journal. Cardiovascular pharmacotherapy2026

Net clinical benefit of extended dual pathway inhibition in chronic coronary syndrome as classified by the 2024 ESC criteria: a COMPASS substudy.

Morten Würtz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.